<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253914</url>
  </required_header>
  <id_info>
    <org_study_id>1188.2</org_study_id>
    <nct_id>NCT02253914</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers</brief_title>
  <official_title>An Investigator Blinded, Randomized, Placebo-controlled Multiple Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the safety, tolerability and pharmacokinetics of BILR 355 BS plus low dose
      ritonavir in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ (area under the concentration time curve of BILR 355 in plasma over one dosing interval at steady state)</measure>
    <time_frame>up to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of BILR 355 in plasma)</measure>
    <time_frame>up to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for BILR 355 BS to achieve steady state</measure>
    <time_frame>up to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss (trough concentration of BILR 355 BS in plasma at steady state)</measure>
    <time_frame>up to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of BILR 355 in plasma)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ (area under the concentration time curve of metabolite 402 in plasma over one dosing interval at steady state)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum concentration of metabolite 402 in plasma)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae (amount of BILR 355 excreted in the urine over the time interval from 0 to the time of the last urine collection interval)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite BILR 402 Ae (amount of BILR 402 excreted in the urine over the time interval from 0 to the time of the last urine collection interval)</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BILR 355 BS, solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BILR 355 BS, tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 BS, solution</intervention_name>
    <arm_group_label>BILR 355 BS, solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 BS, tablet</intervention_name>
    <arm_group_label>BILR 355 BS, tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>BILR 355 BS, solution</arm_group_label>
    <arm_group_label>BILR 355 BS, tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males who meet the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (BP, PR), 12-lead ECG, clinical laboratory tests

               -  No finding deviating from normal (except as noted below) and of clinical
                  relevance

               -  No evidence of a clinically relevant concomitant disease

          2. Age ≥18 years and &lt;60

          3. BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation

        Exclusion Criteria:

          1. Current and medically relevant gastrointestinal, hepatic, renal, respiratory,
             cardiovascular, metabolic, immunological or hormonal disorders

          2. Surgery of gastrointestinal tract (except appendectomy)

          3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          4. History of relevant orthostatic hypotension, fainting spells or blackouts

          5. Chronic or relevant acute infections

          6. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          7. Intake of drugs with a long half-life (&gt;24 hours) within one month prior to
             administration of study drug or during the trial

          8. Use of drugs within 10 days prior to administration or during the trial, which might
             reasonably influence the results of the trial based on the knowledge at the time of
             protocol preparation

          9. Participation in another trial with an investigational drug within one month prior to
             administration or during the trial

         10. Smoker

         11. Inability to refrain from smoking on trial days

         12. Alcohol abuse (more than 60 g/day)

         13. Drug abuse

         14. Recent blood donation (more than 100 mL within 4 weeks prior to administration or
             during the trial)

         15. Excessive physical activities (within 1 week prior to administration or during the
             trial)

         16. Any laboratory value outside the normal reference range that is of clinical relevance

         17. Inability to comply with dietary regimen of study centre

         18. Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B
             surface antigen, hepatitis B core antibody, or hepatitis C antibody positive)

         19. HIV-1 infected as defined by a positive HIV ELISA test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

